German Merck To Double Fund Size And Broaden Corporate VC Focus
Merck of Germany has decided to expand the activities of its corporate venture fund to include all aspects of its business rather than focusing on biopharma. Managing director of Merck Ventures Roel Bulthuis explains what led to the decision and why it won't affect Merck's commitment to innovation in healthcare, and may in fact boost productivity.
You may also be interested in...
Solid US demand for Gonal-f fertility and Rebif MS drugs in the second quarter – along with commissions from its Xalkori co-promotion partnership there with Pfizer – let Merck KGaA upgrade its guidance for the full year.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.